← Back to Search

Communication Improvement Feedback for Cancer Care

N/A
Waitlist Available
Research Sponsored by Duke University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to help improve communication between medical teams and seriously ill patients to ensure the best care.

Who is the study for?
This trial is open to patients within the Duke Health system who are dealing with advanced serious illnesses such as cancer, heart failure, chronic obstructive pulmonary disease (COPD), or dementia. There are no specific exclusion criteria mentioned, so it appears to be quite inclusive.
What is being tested?
The study focuses on improving communication strategies for patients with serious health conditions. It aims to develop and test methods that ensure patient care aligns with their goals and values.
What are the potential side effects?
Since this trial is about feedback and communication strategies rather than medical treatments or drugs, there aren't typical side effects involved. However, participants may experience emotional or psychological impacts from discussing their illness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Frequency of goals of care communication
Timing of goals of care communication

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Feedback to provider regarding frequency and quality of communication
Group II: ControlActive Control1 Intervention
Usual care
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Feedback
2018
N/A
~18170

Find a Location

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,451 Previous Clinical Trials
3,062,070 Total Patients Enrolled
19 Trials studying Dementia
36,219 Patients Enrolled for Dementia
~2222 spots leftby Nov 2025